International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer Focus on HER2-low and Ultralow Categories /
The concept of "HER2-negative" breast cancer is evolving, with the recognition of HER2-low and HER2-ultralow subsets. These subsets are clinically relevant regarding treatment with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which has shown survival benefit in patients with...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2026
|
| Sorozat: | MODERN PATHOLOGY
39 No. 1 |
| Tárgyszavak: | |
| doi: | 10.1016/j.modpat.2025.100925 |
| mtmt: | 36410193 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/39214 |
| LEADER | 04486nab a2200613 i 4500 | ||
|---|---|---|---|
| 001 | publ39214 | ||
| 005 | 20260218085325.0 | ||
| 008 | 260218s2026 hu o 000 eng d | ||
| 022 | |a 0893-3952 | ||
| 024 | 7 | |a 10.1016/j.modpat.2025.100925 |2 doi | |
| 024 | 7 | |a 36410193 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rakha Emad A. | |
| 245 | 1 | 0 | |a International Expert Consensus Recommendations for HER2 Reporting in Breast Cancer |h [elektronikus dokumentum] : |b Focus on HER2-low and Ultralow Categories / |c Rakha Emad A. |
| 260 | |c 2026 | ||
| 300 | |a 14 | ||
| 490 | 0 | |a MODERN PATHOLOGY |v 39 No. 1 | |
| 520 | 3 | |a The concept of "HER2-negative" breast cancer is evolving, with the recognition of HER2-low and HER2-ultralow subsets. These subsets are clinically relevant regarding treatment with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd), which has shown survival benefit in patients with metastatic carcinoma with minimal HER2 protein expression that lack HER2 gene amplification by in situ hybridisation (ISH). In clinical trials using T-DXd, HER2-low was defined as immunohistochemistry (IHC) score 1+ or IHC score 2+ without HER2 gene amplification. HER2-ultralow was defined as faint or barely perceptible, incomplete membrane staining in >0 to ≤10% of tumour cells (IHC score 0+/with membrane staining) and HER2-null as complete absence of staining (IHC score 0/absent membrane staining). These results now necessitate more detailed evaluation and reporting of traditional "HER2-negative" results to identify patients with metastatic breast cancer who may benefit from T-DXd therapy. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have extended regulatory approval of T-DXd to patients with metastatic breast cancer showing HER2-low or HER2-ultralow expression. Updated clinical management guidelines now, therefore, incorporate the spectrum of HER2 results into treatment selection algorithms in the metastatic setting. To align histopathologic practice with these developments, the College of American Pathologists (CAP) has issued a new biomarker-reporting template that recommends explicit distinction between IHC 0/absent membrane staining and IHC 0+/with membrane staining. Key concerns among pathologists include assay variability, scoring reproducibility and quality assurance standards for accurately detecting such low levels of HER2 expression. This manuscript provides expert consensus, evidence-based practical recommendations for identifying and reporting tumours with HER2-low and HER2-ultralow expression. We emphasise standardised testing protocols, validated assays, robust internal and external controls, and focused training for pathologists. A universal structured pathology report is proposed to highlight the accurate distinction between IHC 0 (null), IHC 0+ (ultralow), and HER2-low expression. | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Tan Puay Hoon |e aut |
| 700 | 0 | 2 | |a Van Bockstal Mieke R. |e aut |
| 700 | 0 | 2 | |a Allison Kimberly H. |e aut |
| 700 | 0 | 2 | |a Brogi Edi |e aut |
| 700 | 0 | 2 | |a Callagy Grace |e aut |
| 700 | 0 | 2 | |a Cserni Gábor |e aut |
| 700 | 0 | 2 | |a Jaffer Shabnam |e aut |
| 700 | 0 | 2 | |a Foschini Maria Pia |e aut |
| 700 | 0 | 2 | |a Gobbi Helenice |e aut |
| 700 | 0 | 2 | |a Kulka Janina |e aut |
| 700 | 0 | 2 | |a Li Xiaoxian |e aut |
| 700 | 0 | 2 | |a Provenzano Elena |e aut |
| 700 | 0 | 2 | |a Shaaban Abeer M. |e aut |
| 700 | 0 | 2 | |a Tse Gary M. |e aut |
| 700 | 0 | 2 | |a Varga Zsuzsanna |e aut |
| 700 | 0 | 2 | |a Vincent-Salomon Anne |e aut |
| 700 | 0 | 2 | |a Yamaguchi Rin |e aut |
| 700 | 0 | 2 | |a Yang Wentao |e aut |
| 700 | 0 | 2 | |a ElSheikh Soha |e aut |
| 700 | 0 | 2 | |a Bhargava Rohit |e aut |
| 700 | 0 | 2 | |a De Brot Marina |e aut |
| 700 | 0 | 2 | |a Canas-Marques Rita |e aut |
| 700 | 0 | 2 | |a Marchiò Caterina |e aut |
| 700 | 0 | 2 | |a Warren Madhuri V |e aut |
| 700 | 0 | 2 | |a van Deurzen Carolien H M |e aut |
| 700 | 0 | 2 | |a Mir Yasmeen |e aut |
| 700 | 0 | 2 | |a Deb Rahul |e aut |
| 700 | 0 | 2 | |a Wen Hannah |e aut |
| 700 | 0 | 2 | |a Ellis Ian O. |e aut |
| 700 | 0 | 2 | |a Kollaborációs szervezet: UK National Coordinating Committee of Breast Pathology |e aut |
| 700 | 0 | 2 | |a Kollaborációs szervezet: Association of Breast Pathology |e aut |
| 700 | 0 | 2 | |a Kollaborációs szervezet: European Working Group for Breast Screening Pathology |e aut |
| 700 | 0 | 2 | |a Kollaborációs szervezet: International Society of Breast Pathology |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/39214/1/ModPathol-2026-39-100925-HER2low-Rakha.pdf |z Dokumentum-elérés |